Management of familial hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Journal of Clinical Lipidology

Volumn 5, Issue 3 SUPPL., 2011, Pages

  Ito, Matthew K ^a   McGowan, Mary P ^b   Moriarty, Patrick M ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b Concord Hospital   (United States)

^c UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIFUNGAL AGENT; ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PITAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STATIN;

ALCOHOL CONSUMPTION; APHERESIS; ARTICLE; BODY WEIGHT; BREAST FEEDING; CALORIC INTAKE; CHOLESTEROL INTAKE; CHOLESTEROL SYNTHESIS; CONSTIPATION; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCURONIDATION; HEALTH CARE ORGANIZATION; HOT FLUSH; HUMAN; LIFESTYLE MODIFICATION; MYOPATHY; MYOSITIS; NATIONAL LIPID ASSOCIATION EXPERT PANEL; NUTRITIONAL COUNSELING; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK FACTOR; SIDE EFFECT;

ADULT; BLOOD COMPONENT REMOVAL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; LIPOPROTEINS, LDL; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 79956277910     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.04.001     Document Type: Article

References (84)

1. American Heart Association Executive Summary: Heart Disease and Stroke Statistics 2011 Update: A Report from the American Heart Association. American Heart Association Heart Disease and Stroke Statistics Writing Group Circulation 123 2011 459 463
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia Cr Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic and molecular basis of inherited disease 2001 McGraw Hill New York 2863 2913
4. A.J. Whitfield, P.H. Barrett, F.M. van Bockxmeer, and J.R. Burnett Lipid disorders and mutations in the Apo B gene Clin Chem 50 2004 1725 1732 (Pubitemid 39298000)
5. J.D. Horton, J.C. Cohen, and H.H. Hobbs PCSK9: A convertase that coordinates LDL catabolism J Lipid Res 50 2009 S172 S177
6. P.O. Kwiterovich Jr. Recognition and management of dyslipidemia in children and adolescents J Clin Endocrinol Metab 93 2008 4200 4209 (Pubitemid 352789511)
7. A. Rees Familial hypercholesterolaemia: underdiagnosed and undertreated Eur Heart J 29 2008 2583 2584
8. National Institute for Health and Clinical Excellence. Clinical guidelines and evidence review for familial hypercholesterolemias: the identification and management of adults and children with familial hypercholesterolemia. 2008 (Clinical guidelines 71) www.nice.org.uk/CG71.
9. A.S. Wierzbicki, S.E. Humphries, R. Minhas on behalf of the Guidance Development Group Familial hypercholesterolemia: summary of NICE guidance BMJ 337 2008 509 510
10. S.M. Grundy, J.I. Cleeman, C.N. Merz Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
11. M. Harada-Shiba, T. Sugisawa, and H. Makino Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia J Atheroscler Thromb 17 2010 667 674
12. D.R. Illingworth Management of hypercholesterolemia Med Clin North Am 84 2000 23 42 (Pubitemid 30068890)
13. A.H. Lichtenstein, L.M. Ausman, and S.M. Jalbert Efficacy of Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects J Lipid Res 43 2002 264 273 (Pubitemid 34184013)
14. E. Bruckert, and D. Rosenbaum Lowering LDL cholesterol through diet: potential role in the statin era Curr Opin Lipidol 22 2011 43 48
15. L. Brown, B. Roener, W.W. Willett, and F.M. Sacks Cholesterol lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr 69 1999 30 42 (Pubitemid 29031248)
16. I. Demonty, R.T. Ras, and H.C.M. van der Knaap Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake J Nutr 139 2009 271 284
17. A.M. Dattilo, and P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr 56 1992 320 328
18. A.D. Gepner, M.E. Piper, H.M. Johnson, M.C. Fiore, T.B. Baker, and J.H. Stein Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial Am Heart J 161 2011 145 151
19. W.E. Connor, and S.L. Connor Dietary treatment of familial hypercholesterolemia Arteriosclerosis 9 1Supppl 1989 I91 105
20. M.H. Davidson, P. Toth, and S. Weiss Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia Clin Cardiol 24 2001 467 474 (Pubitemid 32520218)
21. M. Castro Cabezas, J.H. de Vries, A.J. Van Oostrom, J. Iestra, and W.A. van Staveren Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins J Am Diet Assoc 106 2006 1564 1569 (Pubitemid 44415592)
22. A.C. Goldberg, R.E. Ostlund Jr., J.H. Bateman, L. Schimmoeller, T.B. McPherson, and C.A. Spilburg Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs Am J Cardiol 97 2006 376 379 (Pubitemid 43133053)
23. D. Marks, M. Thorogood, H.A. Neil, and S.E. Humphries A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia Atherosclerosis 168 2003 1 14 (Pubitemid 36559596)
24. M.D. Feher, J.C. Webb, and D.D. Patel Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia Atherosclerosis 103 1993 171 180 (Pubitemid 23360931)
25. A. Goldammer, S. Wiltschnig, and G. Heinz Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia Metabolism 51 2002 976 980
26. Scandinavian Simvastatin Survival Study Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
27. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 1998 582 587 (Pubitemid 28182422)
28. P.H. Jones, M.H. Davidson, and E.A. Stein Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2003 152 160 (Pubitemid 36835963)
29. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, and J.S. Morse Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
30. D.E. Cohen, F.A. Anania, and N. Chalasani An assessment of statin safety by hepatologists Am J Cardiol 97 2006 77C 81C
31. P.D. Thompson, P.M. Clarkson, and R.S. Rosenson National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
32. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton National Lipid Association Statin Safety Task Force Liver Expert Panel. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 2006 89C 94C
33. Z. Zhou, E. Rahme, and L. Pilote Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Am Heart J 151 2006 273 281 (Pubitemid 43144726)
34. M. van Heek, C.F. France, and D.S. Compton In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH5825, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther 283 1997 157 163 (Pubitemid 27438958)
35. C. Gagne, D. Gauder, and E. Bruckert Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia Circulation 105 2002 2469 2475 (Pubitemid 34568966)
36. M.J. Zema Colesevelam HCL and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia Am J Ther 12 2005 306 310 (Pubitemid 41391808)
37. J.J.P. Kastelein, F. Adkim, E.S.G. Stroes for the ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
38. I. Hamilton-Craig, K. Kostner, D. Colquhoun, and S. Woodhouse Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia Vasc Health Risk Manag 6 2010 1023 1037
39. G. Avellone, V. Di Garbo, V. Guarnotta, R. Scaglione, G. Parrinello, L. Purpura, D. Torres, and D. Campisi Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia Int Angiol 29 2010 514 524
40. Lipid Research Clinics Program The Lipid Research Clinics coronary primary prevention trial results, I: reduction in the incidence of coronary heart disease JAMA 251 1984 351 364
41. R. Huijgen, E.J. Abbink, and E. Bruckert Trip Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind controlled trial Clin Ther 32 2010 615 625
42. J.M. Drood, P.J. Zimetbaum, and W.H. Frishman Nicotinic acid for the treatment of hyperlipoproteinemia J Clin Pharmacol 31 1991 641 650
43. A.C. Goldberg Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study Am J Cardiol 82 1998 35U 38U (Pubitemid 29047614)
44. J.M. Morgan, D.M. Capuzzi, and J.R. Guyton A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients Am J Cardiol 82 1998 29U 34U (Pubitemid 29047613)
45. J.R. Guyton, and D.M. Capuzzi Treatment of hyperlipidemia with combined niacin-statin regimens Am J Cardiol 82 1998 82U 84U (Pubitemid 29047618)
46. M.L. Wolfe, S.F. Vartanian, and J.L. Ross Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia Am J Cardiol 87 2001 476 479 (Pubitemid 32150014)
47. T.A. Jacobson Myopathy with statin-fibrate combination therapy: clinical considerations Nat Rev Endocrinol 5 2009 507 518
48. J.L. de Gennes, R. Touraine, B. Maunand, J. Truffert, and P. Laudat Homozygous cutaneo-tendinous forms of hypercholesterolemic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment Bull Mem Soc Med Hop Paris 118 1967 1377 1402
49. V. Schettler, E. Wieland, V.W. Armstrong, T. Kleinoeder, R.W. Grunewald, and G.A. Muller Participants of the Gottingen Consensus Conferences. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management Ther Apher 6 2002 381 383 (Pubitemid 35203285)
50. G.R. Thompson LDL apheresis Atherosclerosis 167 2003 1 13 (Pubitemid 36258395)
51. P.M. Moriarty LDL-apheresis therapy Curr Treat Options Cardiovasc Med 8 2006 282 288 (Pubitemid 44083751)
52. A.A. Kroon, M.A. van't Hof, P.N. Demacker, and A.F. Stalenhoef The rebound of lipoproteins after LDL apheresis. Kinetics and estimation of mean lipoprotein levels Atherosclerosis 152 2000 519 526
53. A.D. Marais, R.P. Naoumova, J.C. Firth, C. Penny, C.K. Neuwirth, and G.R. Thompson Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia J Lipid Res 38 1997 2071 2078 (Pubitemid 27468015)
54. M. Pfohl, R.P. Naoumova, and C. Klass Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG CoA reductase inhibitor therapy J Lipid Res 35 1994 1946 1955 (Pubitemid 24353067)
55. D.R. Gordon, S.F. Kelsey, and P.C. Dau Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group Am J Cardiol 81 1998 407 411 (Pubitemid 28099529)
56. R. Tatami, N. Inove, and H. Itoh Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators Atherosclerosis 95 1992 1 13
57. T. Waidner, D. Franzen, and W. Voelker The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study Clin Investig 72 1994 858 863 (Pubitemid 24342968)
58. P. Schuff-Werner, H. Gohike, and U. Bartmann The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL cholesterol plasma concentration and the course of coronary heart disease Eur J Clin Invest 24 1994 724 732 (Pubitemid 24358557)
59. G.R. Thompson, V.M. Maher, and S. Matthews Familial Hypercholesterolemia Regression Study: a randomised trial of low-density-lipoprotein apheresis Lancet 345 1995 811 816
60. A.A. Kroon, W.R. Aengevaeren, and T. van den Werf LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment of coronary atherosclerosis Circulation 93 1996 1826 1835 (Pubitemid 26154034)
61. H. Mabuchi, J. Koizumi, and M. Shimizu Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group Am J Cardiol 82 1998 1489 1495 (Pubitemid 29006472)
62. W.O. Ritcher, M.G. Donner, B. Hofling, and P. Schwandt Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia Metabolism 47 1998 863 868 (Pubitemid 28313196)
63. O. Tamai, H. Matsuoka, H. Itabe, Y. Wada, K. Kohno, and T. Imaizumi Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans Circulation 95 1997 76 82 (Pubitemid 27029946)
64. K. Igarashi, M. Tsuji, M. Nishimura, and M. Horimoto Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia J Clin Apher 19 2004 11 16 (Pubitemid 38509397)
65. M. Sato, and I. Amano Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis Ther Apher Dial 7 2003 419 424 (Pubitemid 37082030)
66. K. Kobayashi, K. Yamashita, and H. Tasaki Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis Ther Apher Dial 8 2004 383 389 (Pubitemid 39600554)
67. C. Keller Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management Ther Apher Dial 11 2007 2 8
68. R. Bambauer Is lipoprotein(a)-apheresis useful? Ther Apher Dial 9 2005 142 147
69. J. Thompsen, and P.D. Thompson A systematic review of LDL apheresis in the treatment of cardiovascular disease Atherosclerosis 189 2006 31 38 (Pubitemid 44444914)
70. U.S. Food and Drug Administration (FDA). PMA final decisions rendered for September 1997. H.E.L.P. Accessed February 8, 2011. Available at http://www.accessdata.fda.gov/cdrh-docs/pdf/p940016.pdf
71. D.F. Loke, O.A. Viegas, L.P. Kek, M. Rauff, A.C. Thai, and S.S. Ratnam Lipid profiles during and after normal pregnancy Gynecol Obstet Invest 32 1991 144 147
72. U. Martin, C. Davies, S. Hayavi, A. Hartland, and F. Dunne Is normal pregnancy atherogenic? Clin Sci (Lond) 96 1999 421 425 (Pubitemid 29179150)
73. A.L. Amundsen, J. Khoury, P.O. Iversen, C. Bergei, L. Ose, and S. Tonstad Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia Atherosclerosis 189 2006 451 457 (Pubitemid 44740297)
74. R. Klingel, B. Gohlen, A. Schwarting, F. Himmelsbach, and R. Straube Differential indication of lipoprotein apheresis during pregnancy Ther Apher Dial 7 2003 359 364 (Pubitemid 36859527)
75. S.M. Grundy United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy Am J Cardiol 88 2001 23J 27J (Pubitemid 32938248)
76. N.J. Stone, S. Bilek, and S. Rosenbaum Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options Am J Cardiol 96 2005 53E 59E (Pubitemid 41140371)
77. E.A. Stein Other therapies for reducing low-density lipoprotein cholesterol: medications in development Endocrinol Metab Clin North Am 38 2009 99 119
78. G.K. Hansson Vaccination against atherosclerosis: science or fiction? Circulation 106 2002 1599 1601
79. M.K. Ito ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense? Ann Pharmacother 41 2007 1669 1678 (Pubitemid 47479796)
80. T.T. Rissanen, and S. Yla-Herttuala Current status of cardiovascular gene therapy Molec Ther 15 2007 1233 1247 (Pubitemid 46965318)
81. A.C. Goldberg NLA Symposium on Familial Hypercholesterolemia. Novel therapies and new targets of treatment familial hypercholesterolemia J Clin Lipidol 4 2010 350 356
82. M.F. Caron, and C.M. White Evaluation of the antihyperlipidemic properties of dietary supplements Pharmacotherapy 21 2001 481 487 (Pubitemid 32275276)
83. L. Badimon, G. Vilahur, and T. Padro Nutraceuticals and atherosclerosis: human trials Cardiovasc Ther 28 2010 202 215
84. M.P. McGowan, and S. Proulx Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep 11 2009 470 476